专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120301495A1 ANTIGEN PEPTIDE AND USE THEREOF 有权
标题翻译：抗原肽及其用途
公开(公告)号：US20120301495A1
公开(公告)日：2012-11-29
申请号：US13380425
申请日：2011-05-23
申请人： Kenichiro Hasumi , Mikio Kuraya
发明人： Kenichiro Hasumi , Mikio Kuraya
IPC分类号： A61K39/05 , C07K14/195 , C12N15/31 , C12Q1/68 , C07K16/12 , A61P31/04 , A61P29/00 , A61P17/10 , C07K7/08 , C12N15/63
CPC分类号： A61K39/0208 , A61K31/7088 , A61K38/164 , A61K39/05 , A61K45/06 , A61K2039/53 , A61K2039/55516 , A61K2039/55588 , A61K2039/58 , A61K2039/645 , A61K2039/70 , C07K14/195 , C07K14/36 , C07K2319/30 , A61K2300/00
摘要： In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes.
摘要翻译：为了提供抗痤疮丙酸杆菌感染的有效疫苗，本发明提供了一种肽，该肽是由特定氨基酸序列组成的肽或由特定氨基酸序列衍生的氨基酸序列组成的肽，通过缺失，取代，插入或添加一个或多个氨基酸，所述肽通过免疫应答抑制由痤疮丙酸杆菌感染引起的炎症。

2. 发明授权

US08784830B2 Antigen peptide and use thereof 有权
标题翻译：抗原肽及其用途
公开(公告)号：US08784830B2
公开(公告)日：2014-07-22
申请号：US13380425
申请日：2011-05-23
申请人： Kenichiro Hasumi , Mikio Kuraya
发明人： Kenichiro Hasumi , Mikio Kuraya
IPC分类号： A61K39/05 , C07K14/195 , C12N15/31 , C12Q1/68 , C07K16/12 , A61P31/04 , A61P17/10 , C07K7/08 , C12N15/63
CPC分类号： A61K39/0208 , A61K31/7088 , A61K38/164 , A61K39/05 , A61K45/06 , A61K2039/53 , A61K2039/55516 , A61K2039/55588 , A61K2039/58 , A61K2039/645 , A61K2039/70 , C07K14/195 , C07K14/36 , C07K2319/30 , A61K2300/00
摘要： In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes.
摘要翻译：为了提供抗痤疮丙酸杆菌感染的有效疫苗，本发明提供了一种肽，该肽是由特定氨基酸序列组成的肽或由特定氨基酸序列衍生的氨基酸序列组成的肽，通过缺失，取代，插入或添加一个或多个氨基酸，所述肽通过免疫应答抑制由痤疮丙酸杆菌感染引起的炎症。

3. 发明授权

US07655393B2 Adoptive immune cells for tumor vaccines 有权
标题翻译：免疫细胞用于肿瘤疫苗
公开(公告)号：US07655393B2
公开(公告)日：2010-02-02
申请号：US11579280
申请日：2004-05-11
申请人： Kenichiro Hasumi , Akira Imaizumi , Masamichi Iwama , Mitsuaki Goto
发明人： Kenichiro Hasumi , Akira Imaizumi , Masamichi Iwama , Mitsuaki Goto
IPC分类号： A01N1/02
CPC分类号： C12N5/0068 , A61K2039/5154 , C12N2533/70
摘要： The present invention provides a method for preparing adoptive immune cells comprising the following steps of a) obtaining mammalian antigen-presenting associated cells; b) culturing the resulting cells in a culture vessel coated with a sugar chain-containing polymer; and c) detaching the cells by shaking the culture vessel without treating the cells with enzyme and without using a cell detaching tool; adoptive immune cells obtained by this preparing method; a culture vessel coated with a sugar chain-containing polymer for use in this preparation method; a kit for preparing an adoptive immune cell vaccine; and a method and a medicine for treating a malignant tumor, type I diabetes, atopic allergic diseases or infections using the adoptive immune cells.
摘要翻译：本发明提供一种制备过继免疫细胞的方法，包括以下步骤：a）获得哺乳动物抗原呈递相关细胞; b）将所得细胞培养在涂有含糖链的聚合物的培养容器中; 和c）通过摇动培养容器而不用酶处理细胞并且不使用细胞分离工具来分离细胞; 通过该制备方法获得的过继免疫细胞; 用该制备方法使用的含糖链聚合物的培养容器; 用于制备过继性免疫细胞疫苗的试剂盒; 以及使用过继免疫细胞治疗恶性肿瘤，I型糖尿病，特应性过敏性疾病或感染的方法和药物。

4. 发明申请

US20090074713A1 DENDRITIC CELL TUMOR INJECTION (DCTI) THERAPY 有权
标题翻译： DENDRIC细胞肿瘤注射（DCTI）治疗
公开(公告)号：US20090074713A1
公开(公告)日：2009-03-19
申请号：US12100878
申请日：2008-04-10
申请人： Kenichiro Hasumi
发明人： Kenichiro Hasumi
IPC分类号： A61K38/20 , A61K38/21 , A61K35/12 , A61P35/00
CPC分类号： A61K31/739 , A61K35/12 , A61K35/15 , A61K36/06 , A61K36/07 , A61K36/074 , A61K38/193 , A61K38/2026 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/5154 , A61K2039/55522 , A61K2300/00
摘要： The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and a lymphocyte cultured medium (LCM) adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and LCM adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with radiation therapy or a chemotherapy regimen.
摘要翻译：本发明涉及一种治疗患者肿瘤细胞的方法，其中从患者的单核细胞发育的未成熟树突状细胞和淋巴细胞培养基（LCM）佐剂直接引入患者的肿瘤细胞。未成熟树突状细胞和LCM佐剂与肿瘤细胞中的抗原结合形成癌症疫苗，从而立即治疗患者的肿瘤细胞。本发明还提供了用放射治疗或化学疗法治疗患者的前体治疗步骤。

5. 发明申请

US20060216269A1 Dendritic cell tumor injection (DCTI) therapy 审中-公开
标题翻译：树突状细胞肿瘤注射（DCTI）治疗
公开(公告)号：US20060216269A1
公开(公告)日：2006-09-28
申请号：US11227374
申请日：2005-09-15
申请人： Kenichiro Hasumi
发明人： Kenichiro Hasumi
IPC分类号： A61K48/00 , A61K38/20 , A61K38/19 , A61K31/739 , A61K36/06
CPC分类号： A61K45/06 , A61K31/739 , A61K35/15 , A61K36/06 , A61K36/07 , A61K36/074 , A61K38/20 , A61K2039/5154 , A61K2300/00
摘要： The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and an adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with a radiation therapy or chemotherapy regimen.
摘要翻译：本发明涉及一种治疗患者肿瘤细胞的方法，其中将从患者的单核细胞发育而来的未成熟树突状细胞和佐剂直接引入患者的肿瘤细胞。未成熟树突状细胞和佐剂与肿瘤细胞中的抗原结合以形成癌症疫苗，从而立即治疗患者的肿瘤细胞。本发明还提供了用放射治疗或化学疗法治疗患者的前体治疗步骤。

6. 发明授权

US09089593B2 Dendritic cell tumor injection (DCTI) therapy 有权
标题翻译：树突状细胞肿瘤注射（DCTI）治疗
公开(公告)号：US09089593B2
公开(公告)日：2015-07-28
申请号：US13303679
申请日：2011-11-23
申请人： Kenichiro Hasumi
发明人： Kenichiro Hasumi
IPC分类号： A61K36/12 , A61K39/39 , A61K35/15 , A61K31/739 , A61K35/12 , A61K36/06 , A61K36/07 , A61K36/074 , A61K38/19 , A61K38/20 , A61K39/00 , A61K45/06
CPC分类号： A61K31/739 , A61K35/12 , A61K35/15 , A61K36/06 , A61K36/07 , A61K36/074 , A61K38/193 , A61K38/2026 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/5154 , A61K2039/55522 , A61K2300/00
摘要： The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and a lymphocyte cultured medium (LCM) adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and LCM adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with radiation therapy or a chemotherapy regimen.
摘要翻译：本发明涉及一种治疗患者肿瘤细胞的方法，其中将从患者的单核细胞发育的未成熟树突状细胞和淋巴细胞培养基（LCM）佐剂直接引入患者的肿瘤细胞。未成熟树突状细胞和LCM佐剂与肿瘤细胞中的抗原结合形成癌症疫苗，从而立即治疗患者的肿瘤细胞。本发明还提供了一种利用放射治疗或化疗方案治疗患者的前体治疗步骤。

7. 发明授权

US08076132B2 Dendritic cell tumor injection (DCTI) therapy 有权
标题翻译：树突状细胞肿瘤注射（DCTI）治疗
公开(公告)号：US08076132B2
公开(公告)日：2011-12-13
申请号：US12100878
申请日：2008-04-10
申请人： Kenichiro Hasumi
发明人： Kenichiro Hasumi
IPC分类号： A61K35/12 , A61K38/20 , A61K38/21 , A61P35/00
CPC分类号： A61K31/739 , A61K35/12 , A61K35/15 , A61K36/06 , A61K36/07 , A61K36/074 , A61K38/193 , A61K38/2026 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/5154 , A61K2039/55522 , A61K2300/00
摘要： The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and a lymphocyte cultured medium (LCM) adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and LCM adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with radiation therapy or a chemotherapy regimen.
摘要翻译：本发明涉及一种治疗患者肿瘤细胞的方法，其中将从患者的单核细胞发育的未成熟树突状细胞和淋巴细胞培养基（LCM）佐剂直接引入患者的肿瘤细胞。未成熟树突状细胞和LCM佐剂与肿瘤细胞中的抗原结合形成癌症疫苗，从而立即治疗患者的肿瘤细胞。本发明还提供了用放射治疗或化学疗法治疗患者的前体治疗步骤。

8. 发明授权

US08075882B2 Adoptive immune cells for tumor vaccines 有权
标题翻译：免疫细胞用于肿瘤疫苗
公开(公告)号：US08075882B2
公开(公告)日：2011-12-13
申请号：US12653090
申请日：2009-12-08
申请人： Kenichiro Hasumi , Akira Imaizumi , Masamichi Iwama , Mitsuaki Goto
发明人： Kenichiro Hasumi , Akira Imaizumi , Masamichi Iwama , Mitsuaki Goto
IPC分类号： A61K35/12 , C12N5/07
CPC分类号： C12N5/0068 , A61K2039/5154 , C12N2533/70
摘要： Adoptive immune cells obtained by a method including (a) obtaining mammalian antigen-presenting associated cells; (b) culturing the resulting cells from step (a) in a culture liquid contained in a culture vessel coated with a sugar chain-containing polymer; and (c) detaching the cells from step (b) by shaking the culture vessel without treating the cells with an enzyme and without using a cell detaching tool. A method for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, by administering the adoptive immune cells to a patient. A pharmaceutical composition for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, including the adoptive immune cells and a pharmaceutically acceptable carrier.
摘要翻译：通过包括（a）获得哺乳动物抗原呈递相关细胞的方法获得的免疫免疫细胞; （b）从包含在含有糖链的聚合物的培养容器中的培养液中培养来自步骤（a）的所得细胞; 和（c）通过摇动培养容器从步骤（b）中分离细胞而不用酶处理细胞，而不使用细胞分离工具。通过向患者施用过继免疫细胞来治疗恶性肿瘤，I型糖尿病，特应性过敏性疾病或感染的方法。用于治疗恶性肿瘤，I型糖尿病，特应性过敏性疾病或感染的药物组合物，包括过继免疫细胞和药学上可接受的载体。

9. 发明申请

US20100266534A1 Human Lymphocyte Vaccine Adjuvant 有权
标题翻译：人类淋巴细胞疫苗佐剂
公开(公告)号：US20100266534A1
公开(公告)日：2010-10-21
申请号：US12824577
申请日：2010-06-28
申请人： Kenichiro Hasumi , Dean LeMar Mann , Kim Graulich Hankey , Kristina Michelle Holt
发明人： Kenichiro Hasumi , Dean LeMar Mann , Kim Graulich Hankey , Kristina Michelle Holt
IPC分类号： A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K39/21 , A61K39/29 , A61K39/08 , A61K39/05 , A61P31/04 , A61P31/18 , A61P31/14 , A61P31/20
CPC分类号： A61K39/39 , A61K2039/55588
摘要： The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.
摘要翻译：本发明涉及来自人淋巴细胞的佐剂。佐剂可以与传统疫苗或癌症免疫治疗组合使用，以增强患者免疫系统对疫苗或其他免疫治疗剂的反应。佐剂来自培养的活化淋巴细胞收集的上清液。

10. 发明授权

US10278992B2 Therapy and methods for introducing immature and dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors 有权
公开(公告)号：US10278992B2
公开(公告)日：2019-05-07
申请号：US15889584
申请日：2018-02-06
申请人： Kenichiro Hasumi
发明人： Kenichiro Hasumi
IPC分类号： A01N63/00 , A61K45/00 , A61K47/00 , A61K35/15 , A61K39/395 , C12N5/0784 , C12N5/0783 , A61K35/17 , C07K16/24 , A61K38/19 , A61K39/00
摘要： The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式